Ravi A. Madan

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 415 citations · Full text

Medicine, Oncology, Pharmacology +17

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Ravi A. Madan, Mahsa Mohebtash, Philip M. Arlen et al. · The Lancet Oncology · 2012 · 327 citations · Full text

Medicine, Immunology, Oncology +17

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David James VanderWeele, Ravi A. Madan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

James L. Gulley, Philip M. Arlen, Ravi A. Madan et al. · Cancer Immunology Immunotherapy · 2009 · 298 citations · Full text

Medicine, Immunology, Oncology +17

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan et al. · The Lancet Oncology · 2017 · 295 citations · Full text

Medicine, Oncology, Pharmacotherapy +11